# Mesa Laboratories Inc: financial statements, quarterly

MLAB · Nasdaq · CIK 724004 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/mlab.md) · [Financials](/companies/mlab/financials.md) · [Filings](/companies/mlab/filings.md) · [Insiders](/companies/mlab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mlab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [53.2](/filings/0001437749-24-033745.md) | [53.5](/filings/0001437749-25-002662.md) | [58.9 d](/filings/0000724004-26-000047.md) | [58.2](/filings/0001437749-25-024715.md) | [57.8](/filings/0000724004-25-000013.md) | [62.8](/filings/0000724004-26-000016.md) | [62.1 d](/filings/0000724004-26-000047.md) | [59.5](/filings/0001437749-26-026808.md) | [60.7](/filings/0000724004-25-000013.md) | [65.1](/filings/0000724004-26-000016.md) | [63.7 d](/filings/0000724004-26-000047.md) | [60.1](/filings/0001437749-26-026808.md) |
| Cost of revenue | $m | [21.1](/filings/0001437749-24-033745.md) | [20.1](/filings/0001437749-25-002662.md) | [22.3 d](/filings/0000724004-26-000047.md) | [20.9](/filings/0001437749-25-024715.md) | [22.4](/filings/0000724004-25-000013.md) | [23.1](/filings/0000724004-26-000016.md) | [23.7 d](/filings/0000724004-26-000047.md) | [22.6](/filings/0001437749-26-026808.md) | [23.4](/filings/0000724004-25-000013.md) | [23.3](/filings/0000724004-26-000016.md) | [21.5 d](/filings/0000724004-26-000047.md) | [21.1](/filings/0001437749-26-026808.md) |
| Gross profit | $m | [32.1](/filings/0001437749-24-033745.md) | [33.4](/filings/0001437749-25-002662.md) | [36.6 d](/filings/0000724004-26-000047.md) | [37.2](/filings/0001437749-25-024715.md) | [35.5](/filings/0000724004-25-000013.md) | [39.8](/filings/0000724004-26-000016.md) | [38.4 d](/filings/0000724004-26-000047.md) | [36.9](/filings/0001437749-26-026808.md) | [37.3](/filings/0000724004-25-000013.md) | [41.8](/filings/0000724004-26-000016.md) | [42.2 d](/filings/0000724004-26-000047.md) | [39.0](/filings/0001437749-26-026808.md) |
| Research and development | $m | [5.0](/filings/0001437749-24-033745.md) | [4.3](/filings/0001437749-25-002662.md) | [5.2 d](/filings/0000724004-26-000047.md) | [4.7](/filings/0001437749-25-024715.md) | [4.6](/filings/0000724004-25-000013.md) | [5.1](/filings/0000724004-26-000016.md) | [5.1 d](/filings/0000724004-26-000047.md) | [5.0](/filings/0001437749-26-026808.md) | [5.0](/filings/0000724004-25-000013.md) | [5.0](/filings/0000724004-26-000016.md) | [5.2 d](/filings/0000724004-26-000047.md) | [4.7](/filings/0001437749-26-026808.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.1)](/filings/0001437749-24-033745.md) | [(0.1)](/filings/0001437749-25-002662.md) | [(271) d](/filings/0000724004-26-000047.md) | [5.6](/filings/0001437749-25-024715.md) | [3.5](/filings/0000724004-25-000013.md) | [5.8](/filings/0000724004-26-000016.md) | [1.5 d](/filings/0000724004-26-000047.md) | [3.1](/filings/0001437749-26-026808.md) | [4.7](/filings/0000724004-25-000013.md) | [8.0](/filings/0000724004-26-000016.md) | [2.7 d](/filings/0000724004-26-000047.md) | [7.0](/filings/0001437749-26-026808.md) |
| Interest expense | $m | [0.9](/filings/0001437749-23-030285.md) | [1.9](/filings/0001437749-24-003053.md) | [1.9 d](/filings/0001437749-24-021606.md) | [2.8](/filings/0001437749-25-024715.md) | [3.0](/filings/0000724004-25-000013.md) | [2.8](/filings/0000724004-26-000016.md) | [2.5 d](/filings/0000724004-26-000047.md) | [2.2](/filings/0001437749-26-026808.md) | [2.9](/filings/0000724004-25-000013.md) | [3.0](/filings/0000724004-26-000016.md) | [2.6 d](/filings/0000724004-26-000047.md) | [2.4](/filings/0001437749-26-026808.md) |
| Income tax | $m | [(0.1)](/filings/0001437749-24-033745.md) | [(0.2)](/filings/0001437749-25-002662.md) | [(20.7) d](/filings/0000724004-26-000047.md) | [0.5](/filings/0001437749-25-024715.md) | [0.4](/filings/0000724004-25-000013.md) | [(0.5)](/filings/0000724004-26-000016.md) | [7.6 d](/filings/0000724004-26-000047.md) | [2.3](/filings/0001437749-26-026808.md) | [(0.5)](/filings/0000724004-25-000013.md) | [1.0](/filings/0000724004-26-000016.md) | [2.5 d](/filings/0000724004-26-000047.md) | [1.5](/filings/0001437749-26-026808.md) |
| Net income | $m | [(1.2)](/filings/0001437749-25-002662.md) | [2.1](/filings/0001437749-25-002662.md) | [(255) d](/filings/0000724004-26-000047.md) | [3.4](/filings/0000724004-26-000016.md) | [3.4](/filings/0000724004-26-000016.md) | [(1.7)](/filings/0000724004-26-000016.md) | [(7.1) d](/filings/0000724004-26-000047.md) | [4.7](/filings/0001437749-26-026808.md) | [2.5](/filings/0000724004-26-000016.md) | [3.6](/filings/0000724004-26-000016.md) | [(4.1) d](/filings/0000724004-26-000047.md) | [2.8](/filings/0001437749-26-026808.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0001437749-24-033745.md) | [0.39](/filings/0001437749-25-002662.md) | not reported | [0.62](/filings/0001437749-25-024715.md) | [0.63](/filings/0000724004-25-000013.md) | [(0.31)](/filings/0000724004-26-000016.md) | not reported | [0.85](/filings/0001437749-26-026808.md) | [0.45](/filings/0000724004-25-000013.md) | [0.65](/filings/0000724004-26-000016.md) | not reported | [0.49](/filings/0001437749-26-026808.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0001437749-24-033745.md) | [0.39](/filings/0001437749-25-002662.md) | not reported | [0.63](/filings/0001437749-25-024715.md) | [0.63](/filings/0000724004-25-000013.md) | [(0.31)](/filings/0000724004-26-000016.md) | not reported | [0.87](/filings/0001437749-26-026808.md) | [0.45](/filings/0000724004-25-000013.md) | [0.66](/filings/0000724004-26-000016.md) | not reported | [0.50](/filings/0001437749-26-026808.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.6](/filings/0001437749-23-030285.md) | [28.2](/filings/0001437749-24-003053.md) | [28.2](/filings/0001437749-25-018586.md) | [28.5](/filings/0001437749-24-024571.md) | [24.3](/filings/0001437749-24-033745.md) | [27.3](/filings/0001437749-25-024715.md) | [27.3](/filings/0000724004-26-000047.md) | [21.3](/filings/0001437749-25-024715.md) | [20.4](/filings/0000724004-25-000013.md) | [29.0](/filings/0000724004-26-000016.md) | [26.9](/filings/0001437749-26-026808.md) | [30.7](/filings/0001437749-26-026808.md) |
| Current assets | $m | [118](/filings/0001437749-23-030285.md) | [118](/filings/0001437749-24-003053.md) | [109](/filings/0001437749-25-018586.md) | [107](/filings/0001437749-24-024571.md) | [108](/filings/0001437749-24-033745.md) | [103](/filings/0001437749-25-024715.md) | [103](/filings/0000724004-26-000047.md) | [98.3](/filings/0001437749-25-024715.md) | [97.4](/filings/0000724004-25-000013.md) | [106](/filings/0000724004-26-000016.md) | [106](/filings/0001437749-26-026808.md) | [103](/filings/0001437749-26-026808.md) |
| Total assets | $m | [637](/filings/0001437749-23-030285.md) | [742](/filings/0001437749-24-003053.md) | [447](/filings/0001437749-25-018586.md) | [440](/filings/0001437749-24-024571.md) | [454](/filings/0001437749-24-033745.md) | [433](/filings/0001437749-25-024715.md) | [433](/filings/0000724004-26-000047.md) | [436](/filings/0001437749-25-024715.md) | [430](/filings/0000724004-25-000013.md) | [435](/filings/0000724004-26-000016.md) | [428](/filings/0001437749-26-026808.md) | [419](/filings/0001437749-26-026808.md) |
| Current liabilities | $m | [39.8](/filings/0001437749-23-030285.md) | [44.2](/filings/0001437749-24-003053.md) | [44.3](/filings/0001437749-25-018586.md) | [54.9](/filings/0001437749-24-024571.md) | [153](/filings/0001437749-24-033745.md) | [164](/filings/0001437749-25-024715.md) | [164](/filings/0000724004-26-000047.md) | [149](/filings/0001437749-25-024715.md) | [48.3](/filings/0000724004-25-000013.md) | [54.4](/filings/0000724004-26-000016.md) | [61.9](/filings/0001437749-26-026808.md) | [57.3](/filings/0001437749-26-026808.md) |
| Total liabilities | $m | [249](/filings/0001437749-23-030285.md) | [339](/filings/0001437749-24-003053.md) | [301](/filings/0001437749-25-018586.md) | [290](/filings/0001437749-24-024571.md) | [293](/filings/0001437749-24-033745.md) | [274](/filings/0001437749-25-024715.md) | [274](/filings/0000724004-26-000047.md) | [263](/filings/0001437749-25-024715.md) | [252](/filings/0000724004-25-000013.md) | [248](/filings/0000724004-26-000016.md) | [242](/filings/0001437749-26-026808.md) | [230](/filings/0001437749-26-026808.md) |
| Long-term debt | $m | not reported | not reported | not reported | [74.1](/filings/0001437749-24-024571.md) | [73.1](/filings/0001437749-24-033745.md) | [72.2](/filings/0001437749-25-002662.md) | [71.3](/filings/0001437749-25-018586.md) | [70.3](/filings/0001437749-25-024715.md) | [69.4](/filings/0000724004-25-000013.md) | [68.4](/filings/0000724004-26-000016.md) | [67.5](/filings/0000724004-26-000047.md) | [66.1](/filings/0001437749-26-026808.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [388](/filings/0001437749-25-002662.md) | [403](/filings/0001437749-25-002662.md) | [145](/filings/0000724004-26-000047.md) | [151](/filings/0000724004-26-000016.md) | [161](/filings/0000724004-26-000016.md) | [155](/filings/0000724004-26-000016.md) | [160](/filings/0001437749-26-026808.md) | [172](/filings/0001437749-26-026808.md) | [178](/filings/0000724004-26-000016.md) | [187](/filings/0000724004-26-000016.md) | [186](/filings/0001437749-26-026808.md) | [189](/filings/0001437749-26-026808.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [9.8 d](/filings/0001437749-24-033745.md) | [11.5 d](/filings/0001437749-25-002662.md) | [12.9 d](/filings/0000724004-26-000047.md) | [10.7](/filings/0001437749-25-024715.md) | [5.3 d](/filings/0000724004-25-000013.md) | [18.1 d](/filings/0000724004-26-000016.md) | [12.7 d](/filings/0000724004-26-000047.md) | [1.9](/filings/0001437749-26-026808.md) | [8.2 d](/filings/0000724004-25-000013.md) | [18.8 d](/filings/0000724004-26-000016.md) | [14.0 d](/filings/0000724004-26-000047.md) | [14.7](/filings/0001437749-26-026808.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001437749-24-033745.md) | [1.1 d](/filings/0001437749-25-002662.md) | [0.5 d](/filings/0000724004-26-000047.md) | [0.9](/filings/0001437749-25-024715.md) | [1.8 d](/filings/0000724004-25-000013.md) | [0.8 d](/filings/0000724004-26-000016.md) | [0.8 d](/filings/0000724004-26-000047.md) | [1.0](/filings/0001437749-26-026808.md) | [1.1 d](/filings/0000724004-25-000013.md) | [0.7 d](/filings/0000724004-26-000016.md) | [0.4 d](/filings/0000724004-26-000047.md) | [0.6](/filings/0001437749-26-026808.md) |
| Dividends paid | $m | [0.9 d](/filings/0001437749-24-033745.md) | [0.9 d](/filings/0001437749-25-002662.md) | [0.9 d](/filings/0000724004-26-000047.md) | [0.9](/filings/0001437749-25-024715.md) | [0.9 d](/filings/0000724004-25-000013.md) | [0.9 d](/filings/0000724004-26-000016.md) | [0.9 d](/filings/0000724004-26-000047.md) | [0.9](/filings/0001437749-26-026808.md) | [0.9 d](/filings/0000724004-25-000013.md) | [0.9 d](/filings/0000724004-26-000016.md) | [0.9 d](/filings/0000724004-26-000047.md) | [0.9](/filings/0001437749-26-026808.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,364](/filings/0001437749-23-030285.md) | [5,360](/filings/0001437749-24-003053.md) | [5,372](/filings/0001437749-24-024571.md) | [5,387](/filings/0001437749-24-033745.md) | [5,396](/filings/0001437749-25-002662.md) | [5,424](/filings/0001437749-25-024715.md) | [5,471](/filings/0000724004-25-000013.md) | [5,429](/filings/0000724004-26-000016.md) | [5,553](/filings/0001437749-26-026808.md) | [5,535](/filings/0000724004-25-000013.md) | [5,565](/filings/0000724004-26-000016.md) | [5,757](/filings/0001437749-26-026808.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,595,869 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001437749-26-026808.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.